{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wardak M"],"funding":["NCI NIH HHS"],"pagination":["6553-62"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3833447"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(20)"],"pubmed_abstract":["Purpose
The primary objective of this study was to investigate whether changes in 3'-deoxy-3'-[¹⁸F]fluorothymidine (¹⁸F-FLT) kinetic parameters, taken early after the start of therapy, could predict overall survival (OS) and progression-free survival (PFS) in patients with recurrent malignant glioma undergoing treatment with bevacizumab and irinotecan.Experimental design
High-grade recurrent brain tumors were investigated in 18 patients (8 male and 10 female), ages 26 to 76 years. Each had 3 dynamic positron emission tomography (PET) studies as follows: at baseline and after 2 and 6 weeks from the start of treatment, ¹⁸F-FLT (2.0 MBq/kg) was injected intravenously, and dynamic PET images were acquired for 1 hour. Factor analysis generated factor images from which blood and "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma."],"pmcid":["PMC3833447"],"funding_grant_id":["P50 CA086306","P50 CA086306-06"],"pubmed_authors":["Dahlbom M","Satyamurthy N","Huang SC","Schiepers C","Cloughesy T","Chen W","Wardak M","Phelps ME","Czernin J"],"additional_accession":[]},"is_claimable":false,"name":"Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.","description":"Purpose
The primary objective of this study was to investigate whether changes in 3'-deoxy-3'-[¹⁸F]fluorothymidine (¹⁸F-FLT) kinetic parameters, taken early after the start of therapy, could predict overall survival (OS) and progression-free survival (PFS) in patients with recurrent malignant glioma undergoing treatment with bevacizumab and irinotecan.Experimental design
High-grade recurrent brain tumors were investigated in 18 patients (8 male and 10 female), ages 26 to 76 years. Each had 3 dynamic positron emission tomography (PET) studies as follows: at baseline and after 2 and 6 weeks from the start of treatment, ¹⁸F-FLT (2.0 MBq/kg) was injected intravenously, and dynamic PET images were acquired for 1 hour. Factor analysis generated factor images from which blood and ","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Oct","modification":"2025-06-01T02:47:32.971Z","creation":"2025-06-01T02:47:32.971Z"},"accession":"S-EPMC3833447","cross_references":{"pubmed":["21868765"],"doi":["10.1158/1078-0432.ccr-10-3290","10.1158/1078-0432.CCR-10-3290"]}}